<DOC>
	<DOCNO>NCT02724540</DOCNO>
	<brief_summary>The primary aim trial estimate duration hepatic progression-free survival ( HPFS ) participant treat bland embolization ( BE ) , transcatheter arterial Lipiodol chemoembolization ( TACE ) , embolization drug-eluting bead ( DEB ) . The primary hypothesis chemoembolization nearly twice durable bland embolization ; thatis , hazard ratio HPFS 1.76 better .</brief_summary>
	<brief_title>Randomized Embolization Trial NeuroEndocrine Tumor Metastases To The Liver</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Participants 18 year old ; Biopsyproven neuroendocrine tumor tumor burden dominant liver . Measurable metastasis liver least one dimension ≥ 1.0 cm . Known extrahepatic disease limit lymph node le 2 cm and/or bone metastasis . Liver tumor burden less equal 70 % . Not candidate surgical resection base unresectability , anatomy , anesthesia risk , patient preference . Symptoms uncontrolled somatostatin analogue OR morphologically progressive tumor RECIST 1.1 criterion liver OR baseline tumor burden &gt; 25 % liver volume . There must plan patient receive concomitant therapy protocol treatment ( Sandostatin BISPhosphanate therapy ) . Presence hepatopetal flow Performance status 02 Zubrod Performance Scale ( see Appendix V ) ; Serum creatinine &lt; 2.0 mg/dl ; Serum Bilirubin ≤ 2.0 Serum albumin ≥ 3.0 Platelet count &gt; 50,000/ul ( correct need ) INR ≤ 1.5 ( correct need ) All patient must inform investigational nature study must sign study specific informed consent accordance institutional federal guideline prior study entry . Pregnant lactate woman may participate due embryotoxic effect protocol treatment . Women/men reproductive potential may participate unless agree use effective contraceptive method . Prior hepatic arterial therapy hepatic radiation therapy . Prior surgical resection ablation liver metastases acceptable . Patients must least one month beyond prior radiotherapy surgery , 6 month beyond chemotherapy recover therapyassociated toxicity . Extensive extrahepatic tumor ( confine lymph nodes/bone metastasis ) Active infection ( Symptomatic bacterial fungal infection newly diagnose and/or require treatment ) ; Choledochoenteric anastomosis ; transpapillary biliary stent , sphincterotomy duodenal papilla Absolute contraindication intravenous iodinate contrast ( Hx significant previous contrast reaction , mitigate appropriate premedication ) . Contraindications arteriography selective visceral catheterization : 1. severe allergy intolerance contrast medium , narcotic , sedative , atropine . 2. bleed diathesis correctable usual form therapy . 3. severe peripheral vascular disease preclude catheterization . Contraindications hepatic artery embolization : 1. high risk hepatic failure , indicated constellation great 50 % liver replacement tumor , LDH &gt; 425 mU/ml , SGOT ( AST ) &gt; 100mU/ml . bilirubin &gt; 2 mg./dl . 2. portal vein occlusion without hepatopedal collateral flow demonstrate angiography ; portal hypertension hepatofugal flow . 3. hepatic encephalopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>